Yes, Apple missed big in Greater China, but Evercore ISI analyst Amit Daryanani said the company has "plenty of offsets" to the pressure there. He called out Apple's "ability to manage China headwinds ...

Evercore ISI analyst Amit Daryanani reiterated an In Line rating and a $22.00 price target on HP (NYSE:HPQ) Enterprise (NYSE:HPE), in light of recent legal developments. The U.S. Department of Justice ...

Evercore ISI analyst Durgesh Chopra maintained a Hold rating on NextEra Energy (NEE – Research Report) yesterday and set a price target of ...

Evercore ISI analyst Eric Boyes maintained a Hold rating on Ashland (ASH – Research Report) yesterday and set a price target of $85.00. The ...

Evercore ISI analyst Kirk Materne is looking past the miss on Azure revenue growth and focusing on a place where he saw "blowout" performance. That's commercial bookings, which were up 75% on a ...

Fintel reports that on January 28, 2025, Evercore ISI Group initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a ...

The release of DeepSeek’s AI model sparked not only market turmoil but also a flurry of activity in Washington, where the ...

We recently published a list of Top 10 AI News You Shouldn’t Miss. In this article, we are going to take a look at where ...

To list the 12 Best Depressed Stocks to Invest in Now, we used a screener to filter out the stocks that are trading close to ...

Akero Therapeutics reports positive mid-stage data for efruxifermin - its candidate treatment for cirrhosis. Akero stock rallied over 100%.